title: Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides.
abstract: The outstanding physio-pathological role played by integrin receptors in living subjects motivates the enormous interest shown by scientists worldwide for this topic. More than twenty years of research has spanned across the structural and functional elucidation of these proteins and over their antagonism-based biomedical applications. The proof-of concept stage, aimed at identifying potent inhibitors, covered a decade of studies, and paved the way for a more advanced era of research where these antagonist molecules were thrown into the deep end of applicative studies. This review intends to summarize the major efforts conducted thus far and focuses on the design, synthesis and biomedical applications of cyclic RGD-containing alpha(v)beta(3) integrin antagonists, in both their small and macromolecular formats. In particular, Chapters 1 and 2 offer a comprehensive outlook on the rational basis for the design of integrin inhibitors, Chapter 3 chronicles the biological and medical applications of monofunctional RGD integrin ligands both in their monomeric and multimeric asset, and Chapter 4 illustrates the potential of RGD-based multifunctional systems in molecular medicine.
authors.affiliation: Istituto di Chimica Biomolecolare del CNR, Traversa La Crucca 3, Li Punti, Sassari I-07100, Italy. luciana.auzzas@icb.cnr.it
authors.forename: L
authors.initials: L
authors.lastname: Auzzas
authors.forename: F
authors.initials: F
authors.lastname: Zanardi
authors.forename: L
authors.initials: L
authors.lastname: Battistini
authors.forename: P
authors.initials: P
authors.lastname: Burreddu
authors.forename: P
authors.initials: P
authors.lastname: Carta
authors.forename: G
authors.initials: G
authors.lastname: Rassu
authors.forename: C
authors.initials: C
authors.lastname: Curti
authors.forename: G
authors.initials: G
authors.lastname: Casiraghi
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008024:Ligands; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D009842:Oligopeptides / Q000737:chemistry*; D010455:Peptides / Q000737:chemistry* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D039302:Integrin alphaVbeta3; D008024:Ligands; D009842:Oligopeptides; D010455:Peptides; C047981:arginyl-glycyl-aspartic acid